Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.

中文翻译：

---

首次批准用于AML的激酶抑制剂。

FLT3的激活突变发生在约30％的急性髓细胞白血病（AML）病例中，并与复发和不良预后有关。Midostaurin是自2000年以来首个获批用于AML的药物，也是首个获批用于FLT3突变亚型的多激酶抑制剂。要查看此长凳到床边，请打开或下载PDF。